Shares of Larimar Therapeutics Inc. sank to new lows Tuesday after the U.S. Food and Drug Administration extended a clinical hold on the biotechnology company's sole pipeline candidate
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
